Skip to main content
. 2021 Jun 8;2021:5514055. doi: 10.1155/2021/5514055

Table 2.

Clinical details.

2020 2019 2018
Admitted N (%) 15 (52) 29 (62) 29 (69)

Treatment N (%)
 Cef/Vanc 13 (45) 25 (53) 28 (64)
 Ofloxacin 14 (48) 17 (36) 7 (16)
 Brolene/PHMB 1 (3) 3 (6) 1 (2)
 Anti viral 0 5 (11) 5 (11)
 Anti fungal 1 (3) 2 (4) 1 (2)
 Not recorded 0 0 3 (7)

Treatment, all patients receiving described treatment, including combination therapy. Cef/Vanc, ceftazidime/vancomycin; PHMB, polyhexamethylene biguanide; others, antifungal and antiviral therapy.